Warburg Pincus led a USD171m Series B for China-based cancer drug developer Haihe Biopharma, with participation from CMB International, Legend Capital, CICC Capital, Beijing Langzi Asiana Asset Management, Chaos Investment, Winfast Holding, and Shanghai International Group, and follow-on from Yingke PE, BioTrack Capital, CSPC Pharmaceutical Group, and Liansheng Ventures. Read more